AWM
BDTX icon

AE Wealth Management’s Black Diamond Therapeutics BDTX Stock Holding History

AE Wealth Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,920
Closed -$46.2K – 1213
2023
Q4 		$46.2K Sell
15,920
-15
-0.1% -$35 ﹤0.01% 1987
2023
Q3 		$45.7K Buy
15,935
+15
+0.1% +$55 ﹤0.01% 1884
2023
Q2 		$80.4K Sell
15,920
-20,000
-56% -$40.8K ﹤0.01% 1823
2023
Q1 		$67.9K Sell
35,920
-27
-0.1% -$62 ﹤0.01% 1807
2022
Q4 		$64.7K Sell
35,947
-10
-0% -$18 ﹤0.01% 1743
2022
Q3 		$61K Sell
35,957
-428
-1% -$1.32K ﹤0.01% 1680
2022
Q2 		$90K Buy
36,385
+11,422
+46% +$26.6K ﹤0.01% 1649
2022
Q1 		$69K Buy
24,963
+8,828
+55% +$32.2K ﹤0.01% 1626
2021
Q4 		$86K Buy
+16,135
New +$113K ﹤0.01% 1645

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

AE Wealth Management's BDTX Position: Q1 2024 in Review

AE Wealth Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2024, closing a stake of 15,920 shares — an estimated $46.2K sold.

AE Wealth Management first reported a position in BDTX in Q4 2021 and held it in 9 quarters. The position peaked at $90K in Q2 2022. 88 funds tracked by Wall St. Rank hold BDTX as of Q1 2024.

  • AE Wealth Management reported no remaining Black Diamond Therapeutics position as of Q1 2024 after selling out during the quarter.
  • AE Wealth Management sold 15,920 Black Diamond Therapeutics shares in Q1 2024, an estimated $46.2K.
  • AE Wealth Management first reported a position in Black Diamond Therapeutics in Q4 2021 and held it in 9 quarters.
  • AE Wealth Management's Black Diamond Therapeutics position peaked at $90K in Q2 2022.
  • 88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2024.

Based on AE Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.